Allogene Therapeutics, Inc. reported a net loss of $41.4 million for the third quarter of 2025, a significant reduction from the $66.3 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company’s net loss was $152.1 million, down from $197.7 million in the prior year. The decrease in losses is attributed to a 30% reduction in operating expenses, which totaled $44.9 million for the quarter, compared to $71.8 million in the previous year. This decline was primarily driven by lower research and development costs, which fell to $31.2 million from $44.7 million, and a decrease in general and administrative expenses.
The company’s total revenue for the third quarter remained unchanged at zero, reflecting a lack of collaboration revenue, which had previously contributed $22,000 in the same quarter of 2024. Allogene's financial position as of September 30, 2025, showed total assets of $439.8 million, a decrease from $548.7 million at the end of 2024. The decline in assets was primarily due to a reduction in cash and cash equivalents, which fell to $37.8 million from $75.2 million, and a decrease in long-term investments.
Strategically, Allogene has made significant adjustments to its workforce, reducing its employee count by approximately 28% in May 2025 to streamline operations and focus on clinical programs. This workforce reduction is expected to yield cost savings and was accompanied by a one-time severance expense of $3.3 million. The company is also advancing its clinical pipeline, with ongoing trials for its lead product candidates, including ALLO-316 and ALLO-329, which target various cancers and autoimmune diseases. The ALPHA3 trial for cema-cel is particularly noteworthy, as it has expanded to include over 50 activated trial sites across the U.S. and Canada, with plans for further geographic expansion.
Looking ahead, Allogene anticipates continued operating losses as it invests in research and development to advance its clinical programs. The company reported that it has sufficient cash reserves to fund operations into the second half of 2027, but recognizes the need for additional capital to support its business plan. Allogene plans to raise funds through equity securities, debt financing, or other sources, which may be necessary to sustain its operations and development activities. The company remains focused on its core clinical programs while exploring strategic partnerships to enhance its product development efforts.
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company developing genetically engineered allogeneic CAR T cell therapies for cancer and autoimmune diseases. Its off-the-shelf T cell products, derived from healthy donors, target antigens like CD19 and CD70 to treat hematologic malignancies, solid tumors, and autoimmune disorders. The company’s platform emphasizes scalable manufacturing, reduced graft-versus-host disease risk, and faster patient access compared to autologous therapies.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.